Appeals Court Rejects AstraZeneca’s IRA Suit, Including the Definition of ‘Drug’ Element
Shares:
Pretty much every page of the new IQVIA “Global Trends in R&D 2024” report is worth deep consideration. It is the definitive atlas of how and where biopharma is investing
Well, this is a fitting end to a wild week. We now have the 15 medicines that will go through the next round of price-setting “negotiations” with CMS. Here are
Lots of earnings this morning that I haven’t processed yet. Hoping to give those a good look this weekend. Until then … The government formally responded to AstraZeneca’s lawsuit alleging